UNDERWRITER COMMON STOCK PURCHASE WARRANT BIOSIG TECHNOLOGIES, INC.Security Agreement • June 29th, 2022 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus
THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to 5:00 p.m. (New York City time) on June __, 2027 (the “Termination Date”), but not thereafter, to subscribe for and purchase from BioSig Technologies, Inc., a Delaware corporation (the “Company”), up to ______1 shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain underwriting agreement, dated as of June __, 2022, by and among the Company and Laidlaw & Company (UK) Ltd., as representative
4,341,667 Shares BIOSIG TECHNOLOGIES, INC. Common Stock AMENDED AND RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • June 29th, 2022 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
BioSig Technologies, Inc., a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”), on a best efforts basis, 4,341,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). This Amended and Restated Underwriting Agreement amends, restates and supersedes in its entirety the prior underwriting agreement dated as of June 24, 2022, by and between the Company and the Representative.
